7 Red Days In A Row: Allstate Stock Is Down 13%

A week of consistent selling has put the insurer's stock in the spotlight.

Allstate (ALL) stock has now moved lower for 7 consecutive trading days, a slide that has delivered a cumulative loss of 13%. That streak has erased about $8.4 billion from the company's market value, which now stands at about $58 billion. For anyone holding the stock, this sharp, persistent move resets the conversation around its current price.

ALL Versus The S&P 500, Streak, And Beyond

Here is how ALL stock stacks up against the S&P 500 over the streak and the periods around it:

What does the data show about this selling?

The selling pressure appears specific to this stock. Over the same 7 trading days, the S&P 500 returned +1.1%. The sources available do not show why the move happened. Allstate stock trades at about $225.66 a share as of 9/23/2026.

Here is how the fundamentals compare with S&P 500 financial stocks. Revenue over the last twelve months grew 5.6%, while the median revenue growth among S&P 500 Financials stocks was 10.2%. The stock also trades at a price-to-earnings multiple of 4.3, well below the median of 13.6 for its sector.

While significant, this kind of streak is not unique in the current market. There are 20 other S&P 500 stocks currently on losing streaks of 7 days or more.

How should an investor treat a streak?

A streak is information, not an instruction. It tells you that a stock has sustained momentum and market attention, but it does not tell you whether the new price is fair, too low, or still too high.

The disciplined response is to use the new price as a reason to re-evaluate the business. The numbers here provide a starting point for checking whether the company's performance justifies a valuation that has changed so quickly.

A slide like this poses an obvious follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.

Those watching the group rather than this one name have another route: our ETF Scorecard shows how the financial funds stack up. Any one of those funds is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.

Weakness In One Name Should Be Noise, Not News

For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.

Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else's drama.